Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Nephrology

Finding the Root Cause: Comprehensive Testing

At a Glance

Membranoproliferative glomerulonephritis (MPGN) is a pattern of kidney injury, not a single disease. Doctors test for infections, autoimmune conditions, abnormal monoclonal proteins, and complement-system problems because finding the cause determines the most appropriate treatment.

Identifying a “pattern of injury” on your kidney biopsy is only the first chapter of your story. Because MPGN is a reflection of damage rather than the damage itself, your care team must act as medical detectives to find the root cause [1][2].

Think of your kidney like a lawn that is turning brown. The “brown lawn” is the MPGN pattern. To fix it, you need to know if the problem is a lack of water, a pest infestation, or a chemical spill. Treating the lawn without knowing the cause won’t work. In the same way, your treatment depends on identifying the driver behind the injury [1].

Investigating Immune-Complex MPGN (IC-MPGN)

If your biopsy shows deposits of both antibodies (immunoglobulins) and complement proteins, your doctors will look for a “secondary cause.” This means something else in your body is triggering your immune system to create clumps that get stuck in your kidneys [3].

  • Chronic Infections: The most common triggers are Hepatitis B, Hepatitis C, and HIV [1][4]. Doctors also look for “hidden” bacterial infections, such as endocarditis (an infection of the heart valves) or lingering bone infections [5].
  • Autoimmune Diseases: Conditions like Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis, or Sjögren’s Syndrome can cause the body to attack its own tissues, leading to IC-MPGN [6][1].
  • Monoclonal Gammopathies: In some patients—particularly those over age 50—a small population of white blood cells may produce an “error” protein called a monoclonal protein [7]. This is often called Monoclonal Gammopathy of Renal Significance (MGRS). Even if it isn’t cancer, these proteins can be highly toxic to the kidneys [8].

Investigating C3 Glomerulopathy (C3G)

If your biopsy shows a C3-dominant pattern without significant antibodies, the problem may be an “overactive” alternative complement pathway [3]. This pathway is part of your immune system that is always “on” to fight germs, but in C3G, the “off switch” is broken [9]. Secondary causes like infections or monoclonal proteins must still be ruled out, as they can sometimes produce this C3-dominant pattern.

To find out why the regulation is broken, your doctor may order a Comprehensive Complement Assessment, though not every test is mandatory for every patient:

  • Complement Levels: Testing for C3, C4, and CH50 or AH50 to see how much of these proteins are being used up [10][11].
  • Autoantibodies: The most common is the C3 Nephritic Factor (C3NeF), an antibody that stabilizes a specific enzyme, keeping your complement system in a state of constant attack [12][13]. Other tests look for antibodies against Factor H or Factor I, which are the natural “brakes” of the system [14].
  • Genetic Testing: In some cohorts, a mutation in genes like CFH, CFI, or C3 is identified in 17% to 43% of cases [15][16]. However, variants of uncertain significance are common. Knowing you have a genetic variant can help inform counseling and risk assessment, though it does not rigidly predict your individual course or if it might return after a kidney transplant [17].

Why Finding the Cause Matters

The “cause-first” approach is critical because the treatments are vastly different:

  • For Infection: Treating the underlying virus (like Hep C) may improve or stop further injury, though existing scarring may persist [1].
  • For Monoclonal Proteins: Doctors may use “clone-directed therapy” (similar to light chemotherapy) to stop the cells making the toxic protein [3].
  • For C3G: Treatment may involve newer complement inhibitors—medications designed to target the specific part of the immune system that is overactive [18].

A Checklist for Your Workup

To ensure no stone is left unturned, a complete tailored evaluation should often include:

  1. Viral Screen: Hepatitis B, C, and HIV [1].
  2. Autoimmune Screen: ANA, dsDNA, and Rheumatoid Factor [6].
  3. Monoclonal Screen: SPEP (Serum Protein Electrophoresis) and UPEP (Urine) alone are not enough; serum immunofixation and Serum Free Light Chain (sFLC) must be included [19].
  4. Complement Panel: Functional assays and autoantibody tests (C3NeF) guided by a specialist [11].
  5. Genetic Panel: Looking for variants in the complement genes, often accompanied by genetic counseling [15].

Common questions in this guide

Why do I need more tests after an MPGN kidney biopsy?
MPGN describes a pattern of kidney injury rather than one single disease. Additional testing looks for infections, autoimmune conditions, abnormal monoclonal proteins, or complement-system problems because treatment depends on the underlying cause.
What blood and urine tests are part of an MPGN workup?
A tailored workup may include hepatitis B, hepatitis C, and HIV testing; autoimmune tests such as ANA, dsDNA, and rheumatoid factor; and a monoclonal protein screen. The monoclonal screen should include serum and urine protein electrophoresis, serum immunofixation, and serum free light chains, not just the first two tests.
What does a C3-dominant biopsy result mean?
A C3-dominant pattern can suggest C3 glomerulopathy, in which part of the immune system called the alternative complement pathway is overactive. Infections and monoclonal proteins can sometimes create a similar pattern, so doctors usually rule them out and may order C3, C4, CH50 or AH50, and selected complement antibody tests.
Do I need genetic testing for MPGN or C3 glomerulopathy?
Genetic testing may be considered when complement-system dysregulation is suspected, but it is not mandatory for every patient. A result can support counseling and risk assessment, while a variant of uncertain significance may not explain the disease or predict an individual course.
How can the underlying cause change my MPGN treatment?
Treating an underlying infection may slow or stop further kidney injury, although existing scar tissue may remain. Monoclonal proteins may be treated with clone-directed therapy, while C3 glomerulopathy may be treated with complement inhibitors when appropriate.
Could lupus or Sjögren syndrome be causing my MPGN?
Yes. Autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and Sjögren syndrome can trigger immune-complex MPGN. Blood tests and your medical history help the care team decide whether an autoimmune condition is contributing.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on membranoproliferative glomerulonephritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific tests have we run to rule out chronic infections like Hepatitis B, Hepatitis C, or endocarditis?
  2. 2.Have I had a full 'monoclonal screen' (SPEP, UPEP, and sFLC), and should we consider a bone marrow biopsy if these are inconclusive?
  3. 3.Since my biopsy showed C3 dominance, which specialized lab are we using for my complement panel (C3NeF, anti-Factor H, etc.)?
  4. 4.Do you recommend genetic testing for my complement system, and how will those results change my immediate treatment plan?
  5. 5.Is there any evidence of an autoimmune condition like lupus or Sjögren’s that could be causing this 'pattern of injury' in my kidneys?

References

References (19)
  1. 1

    [Diagnosis and treatment of glomerular diseases with a membranoproliferative glomerulonephritis (MPGN) pattern of injury].

    Rudnicki M, Windpessl M, Eller K, et al.

    Wiener klinische Wochenschrift 2023; (135(Suppl 5)):688-695 doi:10.1007/s00508-023-02264-7.

    PMID: 37728653
  2. 2

    A case report of recurrent membranoproliferative glomerulonephritis after kidney transplantation due to ventriculoatrial shunt infection.

    Völker LA, Burkert K, Scholten N, et al.

    BMC nephrology 2019; (20(1)):296 doi:10.1186/s12882-019-1472-1.

    PMID: 31382904
  3. 3

    Finding the etiology of membranoproliferative glomerulonephritis.

    Sethi S

    Kidney international 2026; (110(1)):8-15 doi:10.1016/j.kint.2026.02.030.

    PMID: 41895686
  4. 4

    Membranoproliferative Glomerulonephritis Associated with a Human Immunodeficiency Virus Infection.

    Rafik H, El Amrani M, El Kabbaj D

    Indian journal of nephrology 2017; (27(4)):319-320 doi:10.4103/0971-4065.202838.

    PMID: 28761237
  5. 5

    Membranoproliferative Glomerulonephritis due to Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella Endocarditis in a Patient with Cirrhosis: A Case Report.

    Mehta AN, Malchira RR, Mehta K, Nast CC

    Glomerular diseases 2025; (5(1)):431-437 doi:10.1159/000549196.

    PMID: 41321541
  6. 6

    Primary Sjögren's syndrome presenting with non-diffuse membranoproliferative glomerulonephritis-like lesions in cryoglobulinemic glomerulonephritis: a case report.

    Duan ZY, Cai GY, Chen F, et al.

    Frontiers in immunology 2025; (16()):1610017 doi:10.3389/fimmu.2025.1610017.

    PMID: 40491909
  7. 7

    C3 glomerulonephritis associated with monoclonal gammopathy of renal significance: case report.

    Alonso-Titos J, Perea-Ortega L, Sola E, et al.

    BMC nephrology 2018; (19(1)):129 doi:10.1186/s12882-018-0927-0.

    PMID: 29884135
  8. 8

    The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

    Leung N, Bridoux F, Batuman V, et al.

    Nature reviews. Nephrology 2019; (15(1)):45-59 doi:10.1038/s41581-018-0077-4.

    PMID: 30510265
  9. 9

    Clinico-Pathogenic Similarities and Differences between Infection-Related Glomerulonephritis and C3 Glomerulopathy.

    Wada Y, Kamata M, Miyasaka R, et al.

    International journal of molecular sciences 2023; (24(9)) doi:10.3390/ijms24098432.

    PMID: 37176142
  10. 10

    C3 glomerulopathies: dense deposit disease and C3 glomerulonephritis.

    Ponticelli C, Calatroni M, Moroni G

    Frontiers in medicine 2023; (10()):1289812 doi:10.3389/fmed.2023.1289812.

    PMID: 38076230
  11. 11

    Diagnosis of complement alternative pathway disorders.

    Angioi A, Fervenza FC, Sethi S, et al.

    Kidney international 2016; (89(2)):278-88.

    PMID: 26806831
  12. 12

    Analysis of C3 Nephritic Factors by ELISA.

    Skattum L

    Methods in molecular biology (Clifton, N.J.) 2019; (1901()):177-182 doi:10.1007/978-1-4939-8949-2_13.

    PMID: 30539576
  13. 13

    C3 concentrations can be normal in patients with C3 glomerulopathy secondary to C3 nephritic factor.

    Anderson H, Van Voorthuizen M, O'Donnell J, Beck S

    Journal of clinical pathology 2024; (77(7)):503-506 doi:10.1136/jcp-2023-209319.

    PMID: 38538072
  14. 14

    Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy.

    Chauvet S, Roumenina LT, Aucouturier P, et al.

    Frontiers in immunology 2018; (9()):2260 doi:10.3389/fimmu.2018.02260.

    PMID: 30333829
  15. 15

    High-Throughput Genetic Testing for Thrombotic Microangiopathies and C3 Glomerulopathies.

    Bu F, Borsa NG, Jones MB, et al.

    Journal of the American Society of Nephrology : JASN 2016; (27(4)):1245-53 doi:10.1681/ASN.2015040385.

    PMID: 26283675
  16. 16

    Rare Variants in Complement Gene in C3 Glomerulopathy and Immunoglobulin-Mediated Membranoproliferative GN.

    Meuleman MS, Vieira-Martins P, El Sissy C, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2023; (18(11)):1435-1445 doi:10.2215/CJN.0000000000000252.

    PMID: 37615951
  17. 17

    Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease.

    Caravaca-Fontán F, Díaz-Encarnación MM, Lucientes L, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2020; (15(9)):1287-1298 doi:10.2215/CJN.15241219.

    PMID: 32816888
  18. 18

    Pivotal Clinical Trials in C3 Glomerulopathy: answers and remaining uncertainties.

    Caravaca-Fontan F, Bruchfeld A, Moran SM, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2026; doi:10.1093/ndt/gfag155.

    PMID: 42397131
  19. 19

    Diagnostic performances of M-protein tests according to the clinical presentations of kidney disease.

    Koo EH, Shin JH, Jang HR, et al.

    European journal of internal medicine 2016; (33()):88-92.

    PMID: 27421913

This page is for informational purposes only and does not constitute medical advice. Your nephrologist and relevant specialists should interpret your MPGN workup and discuss treatment with you.